Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Dec 2;116(23):4958-67.
doi: 10.1182/blood-2010-01-266999. Epub 2010 Aug 20.

Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia

Brian Parkin  1 , Harry Erba, Peter Ouillette, Diane Roulston, Anjali Purkayastha, Judith Karp, Moshe Talpaz, Lisa Kujawski, Sajid Shakhan, Cheng Li, Kerby Shedden, Sami N Malek
Affiliations

Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia

Brian Parkin et al. Blood. .

Abstract

Genomic aberrations are of predominant importance to the biology and clinical outcome of patients with acute myelogenous leukemia (AML), and conventional karyotype-based risk classifications are routinely used in clinical decision making in AML. One of the known limitations of cytogenetic analysis is the inability to detect genomic abnormalities less than 5 Mb in size, and it is currently unclear whether overcoming this limitation with high-resolution genomic single-nucleotide polymorphism (SNP) array analysis would be clinically relevant. Furthermore, given the heterogeneity of molecular mechanisms/aberrations that underlie the conventional karyotype-based risk classifications, it is likely that further refinements in genomic risk prognostication can be achieved. In this study, we analyzed flow cytometer-sorted, AML blast-derived, and paired, buccal DNA from 114 previously untreated prospectively enrolled AML patients for acquired genomic copy number changes and loss of heterozygosity using Affymetrix SNP 6.0 arrays, and we correlated genomic lesion load and specific chromosomal abnormalities with patient survival. Using multivariate analyses, we found that having ≥ 2 genomic lesions detected through SNP 6.0 array profiling approximately doubles the risk of death when controlling for age- and karyotype-based risk. Finally, we identified an independent negative prognostic impact of p53 mutations, or p53 mutations and 17p-loss of heterozygosity combined on survival in AML.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Whole genome copy number heatmap display of 114 AML genomes: Copy number heatmap displays for paired DNA samples based on SNP 6.0 array profiling were generated using dChipSNP. (Left panel) Buccal DNA. (Right panel) AML blast DNA. Samples are grouped by AML subtype (primary, secondary, and treatment-related) and by chromosome number (1-22 and X). Blue indicates copy loss, red indicates copy gain. Each column represents one patient.
Figure 2
Figure 2
SNP 6.0 array-based lesion cutoffs and OS in AML (Kaplan-Meier plots). (A-D) All-treatment group. (E-H) Intensive-treatment group.
Figure 3
Figure 3
Specific SNP 6.0 array-based genomic lesions and OS in AML (Kaplan-Meier plots). (A-D) All-treatment group. (E-H) Intensive-treatment group.
Figure 4
Figure 4
SNP 6.0 array-based lesion cutoffs and cytogenetic risk group and OS in AML (Kaplan-Meier plots). (A-D) All-treatment group. (E-H) Intensive-treatment group.
See this image and copyright information in PMC

References

    1. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909–1918. - PubMed
    1. Pedersen-Bjergaard J, Andersen MK, Andersen MT, Christiansen DH. Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia. 2008;22(2):240–248. - PubMed
    1. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100(13):4325–4336. - PubMed
    1. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92(7):2322–2333. - PubMed
    1. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96(13):4075–4083. - PubMed

Publication types

MeSH terms

Substances